United States · Biotechnology startup
United States · Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Funding reportedLast round: Post ipo equity
What company datasets say Entrada Therapeutics raised
Funding, as reported
Reported in all$302Min dollars
Rounds5
Last roundPost ipo equity
Last round dateJun 2024
Investors listed15
Founders and team
From the SEC filings it signed: 5 on the team.
- Dipal DoshiExecutive Officer, Directori
- Kory F. WentworthExecutive Officeri
- Natarajan F. SethuramanExecutive Officeri
- Nathan F. DowdenExecutive Officeri
- Nerissa F. KreherExecutive Officeri
On the board, as filediCarole F. NuechterleinJohn F. CrowleyKush M. ParmarPeter F. KimTodd F. Foley
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Entrada Therapeutics in front of investors. Or tell us what we have wrong.